CDRH fax policy: follow-up hard copies needed for data related to final reviews.
This article was originally published in The Gray Sheet
Executive SummaryCDRH FAX POLICY: FOLLOW-UP WITH "OVERNIGHT" HARD COPIES OF DATA will be required if the faxed information is "in whole or in part the basis for a final review decision" or "an administrative decision that may be treated as a final review decision," according to an internal memo recently circulated within the device center's Office of Device Evaluation. The memo states that sponsors "must follow the fax with a hard copy overnight to [the office's document mail center] to be logged in by the DMC as part of the administrative record prior to the issuance of the final decisions letter."
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.